Tucatinib 150 mg Indian Exporter to USA | Low-Cost Oncology — Ernest Impex

Tukavo 150 mg Tablet: Advanced Targeted Therapy for HER2-Positive Breast Cancer

Are you looking for a reliable Tukavo 150 mg tablet exporter from India? Ernest Impex, a specialized global division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a leading provider of high-integrity oncology medications. We offer professional pharmaceutical logistics and secure bulk supply chains to Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica).

Extensive Product Profile: Understanding Tukavo 150 mg

Tukavo 150 mg Tablet, which contains the active ingredient Tucatinib, is a cutting-edge oral tyrosine kinase inhibitor. It is specifically engineered to target and inhibit the HER2 protein, making it a vital component in the treatment of advanced-stage breast cancers that have overexpressed this specific protein.

1. Clinical Indications & Primary Usage

Tukavo 150 mg is clinically prescribed for the following:

• HER2-Positive Metastatic Breast Cancer: Used in combination with Trastuzumab and Capecitabine for adult patients who have received one or more prior anti-HER2-based regimens.

• Advanced Unresectable Cancer: Targeted for cases where surgery is not an option and the cancer has spread to other parts of the body, including the brain (brain metastases).

2. Detailed Mechanism of Action

Tucatinib, the core molecule in Tukavo, works through a highly selective inhibitory process:

• Selective HER2 Inhibition: Unlike older kinase inhibitors, Tucatinib is highly selective for HER2 with minimal inhibition of EGFR (Epidermal Growth Factor Receptor). This selectivity helps reduce "off-target" side effects like severe skin rashes.

• Signaling Blockade: By binding to the intracellular kinase domain of the HER2 receptor, it blocks the phosphorylation and subsequent signaling pathways (such as PI3K/Akt and MAPK) that tell the cancer cell to grow and divide.

• Brain Penetration: One of the most significant features of Tukavo is its ability to cross the blood-brain barrier, allowing it to treat HER2-positive tumors that have metastasized to the brain.

3. Storage and Handling Protocols

• Temperature: Store at room temperature, ideally between 20°C to 25°C (68°F to 77°F).

• Original Container: Keep the tablets in their original bottle. Do not remove the desiccant (drying agent) from the bottle to protect the medication from moisture.

• Usage Window: Once the bottle is opened, the tablets should typically be used within 3 months.

• Safety: Always keep out of the reach of children and away from high-humidity areas (like bathrooms).

Potential Side Effects of Tukavo 150 mg

While Tukavo is a targeted therapy, it can cause systemic side effects. Patients should be monitored for:

• Gastrointestinal: Severe diarrhea (the most common side effect), nausea, vomiting, and stomatitis (mouth sores).

• Hepatotoxicity: Increased liver enzymes (ALT/AST) and bilirubin; regular liver function tests are mandatory.

• Hand-Foot Syndrome: Redness, swelling, or pain on the palms of the hands or soles of the feet (Palmar-plantar erythrodysesthesia).

• Systemic: Fatigue, decreased appetite, and joint pain.